Tiziana Life Sciences Ltd
TLSA1.695USD
-0.105-5.83%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
201.41MCap. mercado
--P/E TTM
Más Datos de Tiziana Life Sciences Ltd Compañía
Tiziana Life Sciences Ltd. is a United Kingdom-based clinical-stage biotechnology company that is specialized in the developing transformative therapies for neurodegenerative and neuroinflammatory. The Company’s clinical pipeline includes drug assets for secondary progressive multiple sclerosis, Alzheimer’s, and ALS. Its lead immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer’s and other CNS indications. Its Anti IL-6R mAb (TZLS-501), a fully human mAb binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune disease and cancer, reducing circulating levels of the IL-6 cytokine.
Información de Tiziana Life Sciences Ltd
Símbolo de cotizaciónTLSA
Nombre de la empresaTiziana Life Sciences Ltd
Fecha de salida a bolsaNov 20, 2018
Director ejecutivoMr. Ivor Elrifi
Número de empleados- -
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 20
Dirección3rd Floor, 11-12 St. James's Square
CiudadLONDON
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited Kingdom
Código postalSW1Y 4LB
Teléfono442074952379
Sitio Webhttps://www.tizianalifesciences.com/
Símbolo de cotizaciónTLSA
Fecha de salida a bolsaNov 20, 2018
Director ejecutivoMr. Ivor Elrifi
Ejecutivos de Tiziana Life Sciences Ltd
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Willy Jules Simon
Mr. Willy Jules Simon
Non-Executive Independent Director
Non-Executive Independent Director
8.25K
--
Mr. John P. Brancaccio, CPA
Mr. John P. Brancaccio, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Gabriele Marco Antonio Cerrone
Mr. Gabriele Marco Antonio Cerrone
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Ivor Elrifi
Mr. Ivor Elrifi
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Ms. Keeren Shah
Ms. Keeren Shah
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
--
--
Dr. William A. Clementi, Pharm.D.
Dr. William A. Clementi, Pharm.D.
Chief Development Officer
Chief Development Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Willy Jules Simon
Mr. Willy Jules Simon
Non-Executive Independent Director
Non-Executive Independent Director
8.25K
--
Mr. John P. Brancaccio, CPA
Mr. John P. Brancaccio, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Gabriele Marco Antonio Cerrone
Mr. Gabriele Marco Antonio Cerrone
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Ivor Elrifi
Mr. Ivor Elrifi
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Ms. Keeren Shah
Ms. Keeren Shah
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
--
--
Dr. William A. Clementi, Pharm.D.
Dr. William A. Clementi, Pharm.D.
Chief Development Officer
Chief Development Officer
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: jue., 30 de oct
Actualizado: jue., 30 de oct
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Cerrone (Gabriele M)
35.38%
Monica Fonda (Natalia Laura)
5.73%
Chernett (Jorey)
5.01%
Dauntless Investment Group, LLC
2.88%
Citadel Advisors LLC
0.17%
Otro
50.84%
Accionistas
Accionistas
Proporción
Cerrone (Gabriele M)
35.38%
Monica Fonda (Natalia Laura)
5.73%
Chernett (Jorey)
5.01%
Dauntless Investment Group, LLC
2.88%
Citadel Advisors LLC
0.17%
Otro
50.84%
Tipos de accionistas
Accionistas
Proporción
Individual Investor
46.12%
Investment Advisor
3.36%
Investment Advisor/Hedge Fund
0.25%
Hedge Fund
0.18%
Research Firm
0.10%
Otro
49.98%
Participación institucional
Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
67
4.64M
3.91%
+430.59K
2025Q2
68
51.10M
45.84%
+9.72M
2025Q1
69
45.10M
40.46%
+3.34M
2024Q4
64
40.33M
36.45%
-5.07M
2024Q3
58
41.30M
37.43%
-3.04M
2024Q2
51
40.27M
36.45%
-4.04M
2024Q1
48
40.16M
36.35%
-4.27M
2023Q4
52
45.25M
44.24%
+1.19M
2023Q3
58
45.24M
44.24%
+1.10M
2023Q2
54
45.32M
44.32%
+1.19M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Cerrone (Gabriele M)
42.04M
35.38%
+2.70M
+6.85%
Mar 31, 2025
Chernett (Jorey)
5.95M
5.01%
+5.95M
--
Jun 11, 2025
Dauntless Investment Group, LLC
3.42M
2.88%
+1.68M
+96.52%
Jun 30, 2025
Citadel Advisors LLC
198.99K
0.17%
+198.99K
--
Jun 30, 2025
HSBC Global Asset Management (UK) Limited
105.36K
0.09%
--
--
Jun 30, 2025
Zhang Financial LLC
89.76K
0.08%
-6.50K
-6.75%
Jun 30, 2025
Susquehanna International Group, LLP
86.08K
0.07%
+28.75K
+50.16%
Jun 30, 2025
HRT Financial LP
84.11K
0.07%
+13.74K
+19.53%
Jun 30, 2025
Kovitz Investment Group Partners, LLC
79.36K
0.07%
--
--
Jun 30, 2025
Ver más
ETFs relacionados
Actualizado: jue., 6 de nov
Actualizado: jue., 6 de nov
Nombre
Proporción
Fidelity Nasdaq Composite Index ETF
0%
Fidelity Nasdaq Composite Index ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Oct 20, 2021
Merger
2→1
Oct 20, 2021
Merger
2→1
Oct 20, 2021
Merger
2→1
Oct 20, 2021
Merger
2→1
Jul 16, 2020
Split
1→2.5
Fecha
Tipo
Relación
Oct 20, 2021
Merger
2→1
Oct 20, 2021
Merger
2→1
Oct 20, 2021
Merger
2→1
Oct 20, 2021
Merger
2→1
Jul 16, 2020
Split
1→2.5
